help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saunders, M.I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saunders, M.I.
The Oncologist, Vol. 4, No. 1, 11-16, February 1999
© 1999 AlphaMed Press

Head and Neck Cancer: Altered Fractionation Schedules

M.I. Saunders

Marie Curie Research Wing, Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom

Correspondence: M.I. Saunders, M.D., Marie Curie Research Wing, Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, HA6 2RN, United Kingdom. Telephone: 44-1923-844723; Fax: 44-1923-844167; e-mail: mcrw{at}mtvern.co.uk\|[emsp ]\|\|[emsp ]\|

Local control is paramount in the treatment of localized advanced head and neck cancer. Standard radiotherapy cures a high percentage of early tumors—more than 80% of the early laryngeal tumors—but fewer of the advanced tumors. Attempts have therefore been made to improve the therapeutic ratio by: A) hyperfractionation: reducing the dose per fraction to reduce late morbidity; the total dose is then elevated in an attempt to improve local tumor control with equal morbidity, and B) acceleration: reducing the overall treatment time to overcome repopulation during a protracted course of radiotherapy.

The total dose and dose per fraction have been reduced in the accelerated arm in some trials, while in others the total dose has been maintained. Both these strategies have been tested in multicenter randomized controlled trials, but neither have become part of routine clinical practice.

The biological parameters determining local tumor control and normal tissue effects are being studied at Mount Vernon by an analysis of selected randomized controlled trials, with the aim of designing new schedules of radiotherapy for future studies.

Key Words. Head and neck cancer • Altered fractionation • Acceleration • Hyperfractionation • Radiotherapy







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 1999 by AlphaMed Press.